- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03041974
Impact of Microparticles in Blood on Transfused Patient Outcomes (IMIB)
Cell-derived Microparticles in Red Blood Cell (RBC) Concentrates, and Their Potential Impact on Outcomes of Transfused Patients in Critical Care: a Prospective Multicentre National Cohort Study of Patients Included in the ABLE Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
During conservation of red blood cell concentrates, red blood cells (RBCs) undergo biochemical and morphological changes that have been well described, and are collectively termed " storage lesions ". The exact effects of these lesions in terms of beneficial or deleterious implications in the recipient remain to be elucidated. However, several retrospective studies in targeted populations suggest that an increase in the duration of RBC conservation could lead to an increase in morbidity and mortality in transfused patients. The multicenter, prospective trial ABLE (Age of Blood Evaluation, ISRCTN44878718) aimed to evaluate in a randomised clinical trial, the impact of the age of transfused RBC concentrates on several outcomes in critical care patients.
Among the modifications that RBCs undergo during storage, the generation of microparticles from red blood cellsRBCs or residual platelets present in the blood concentrate has never been evaluated in a prospective clinical study. It has been reported that the number of red cell-derived microparticles (RMPs) present in stored blood increases with storage duration. In vivo, microparticles MPs appear to be increasingly involved in disease processes, notably due to their pro-inflammatory and pro-coagulant effects. Furthermore, it has been shown that the antigens of the Rhesus group are expressed on the RBC derived microparticles, and the investigative team has shown that microparticles derived from elsewhere (endothelial cells) are capable of activating cells which are important in the induction of immune responses (dendritic cells). Thus, transfusing red blood cell derived microparticles could participate in post-transfusional alloimmunization which may also be evaluated in this study.
The aim of the IMIB study is to (1) quantify red cell- and platelet-derived microparticles MPs in RBC concentrates, and (2) evaluate the impact of the quantity of transfused microparticles (MPs) on survival and several outcomes in the patients enrolled in the ABLE trial in France.
Other aims are to investigate the relationship between the number of microparticles in RBC units and (1) the age of RBC, (2) donors characteristics, (3) the procedures used to prepare the blood products (to define a potential new "lesion storage" marker).
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria are those of the ABLE trial: patients who
- Have had a request for a first red cell unit transfusion in the Intensive Care Unit (ICU), and
- Have an anticipated length of invasive and/or non-invasive continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BIPAP) mechanical ventilation of at least 48 hours once enrolled, as estimated by the attending physician
Exclusion Criteria:
- less than 18 years of age
- previously enrolled in the ABLE study
- has already been transfused with red cells during the current hospitalisation
- has an obvious terminal illness documented in the medical record with a life expectancy of less than 3 months
- has undergone routine cardiac surgical care
- decision to withdraw/withhold some critical care had been made
- brain dead
- no red cells with a storage time of 7 days or less available in the blood bank that cannot be transported from the blood supplier
- Who require more than 1 unit of uncross-matched red cells
- With a known objection to blood transfusions
- With autologous blood donations
- Who pose difficulties in securing blood products (rare blood groups), and who are difficult to match
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Transfused critical care patients
Patients included in the Age of BLood Evaluation (ABLE) trial in either arms and included in a French center.
|
Flow cytometric quantification of microparticles in transfused blood
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
All cause mortality
Time Frame: 90 days
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All cause mortality
Time Frame: 28 days, 6 months
|
28 days, 6 months
|
|
Multi organ dysfunction score
Time Frame: 6 months
|
6 months
|
|
Nosocomial infection
Time Frame: 6 months
|
including Nosocomial pneumonia, Deep tissue infections (e.g.
peritonitis, mediastinitis), Bacteraemia from organisms not considered normal skin flora and judged important enough to treat by the attending team, as measured while in the ICU
|
6 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Intensive care and Hospital duration of stay
Time Frame: 6 months
|
6 months
|
Length of time requiring respiratory, haemodynamic and renal support
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Francine Garnache-Ottou, PharmD, PhD, Etablissement Français du Sang, Besançon
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IMIB PHRC 2013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Care
-
Potrero MedicalCompletedCritical Care, Intensive Care
-
Hospital Israelita Albert EinsteinActive, not recruitingCritical Care | Intensive Care UnitBrazil
-
University College, LondonCompleted
-
Hospital do CoracaoD'Or Institute for Research and Education; Sociedade Hospital SamaritanoCompleted
-
Hospital Israelita Albert EinsteinMinistry of Health, BrazilNot yet recruitingTelemedicine | Critical Care | Intensive Care Units
-
Hospital Nossa Senhora da ConceicaoRecruiting
-
Hospices Civils de LyonRecruiting
-
University Hospital, ToursCompleted
-
Hospitech RespirationCompleted
-
InLight SolutionsLuminous MedicalCompletedCritical CareUnited States
Clinical Trials on Red Blood Cell transfusion
-
Bristol-Myers SquibbActive, not recruitingLower-risk Myelodysplastic SyndromesJapan
-
NHS Blood and TransplantUniversity of York; British Medical Research CouncilTerminatedSickle Cell DiseaseUnited Kingdom
-
Sanquin Research & Blood Bank DivisionsNetherlands: Ministry of Health, Welfare and SportsWithdrawnMyelodysplastic SyndromesNetherlands
-
Hvidovre University HospitalIMK FondenUnknown
-
Fundació Institut de Recerca de l'Hospital de la...UnknownCirrhosis | Portal Hypertension | Upper Gastrointestinal BleedingSpain
-
Mayo ClinicDuke University; Blood Systems Research InstituteCompletedBlood Transfusion ComplicationsUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedCancer | SurgeryFrance
-
Australian and New Zealand Intensive Care Research...Not yet recruitingExtracorporeal Membrane Oxygenation Complication | Blood Loss Anemia
-
Juan PascualActive, not recruitingGlucose Transporter Type 1 Deficiency Syndrome | GLUT1DS1United States
-
University Hospital TuebingenGerman Research FoundationCompletedAnemia of PrematurityGermany, Denmark